FAM
CORT icon

Fred Alger Management’s Corcept Therapeutics CORT Stock Holding History

Fred Alger Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,248
Closed -$252K – 438
2026
Q1 		$252K Buy
+6,248
New +$234K ﹤0.01% 408
2025
Q4 		– Sell
-4,049
Closed -$337K – 475
2025
Q3 		$337K Buy
+4,049
New +$293K ﹤0.01% 409

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fred Alger Management's CORT Position: Q2 2026 in Review

Fred Alger Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 6,248 shares — an estimated $252K sold.

Fred Alger Management first reported a position in CORT in Q3 2025 and held it in 2 quarters. The position peaked at $337K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Fred Alger Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fred Alger Management sold 6,248 Corcept Therapeutics shares in Q2 2026, an estimated $252K.
  • Fred Alger Management first reported a position in Corcept Therapeutics in Q3 2025 and held it in 2 quarters.
  • Fred Alger Management's Corcept Therapeutics position peaked at $337K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.